Log in to search using one of your social media accounts:

 

Parents sue for daughter to use medical marijuana
An 11-year-old girl with leukemia suffers seizures due to years of chemotherapy. Her parents are suing the Chicago school district for banning her use of medical marijuana. (Source: the Mail online | Health)
Source: the Mail online | Health - January 12, 2018 Category: Consumer Health News Source Type: news

Parents sue for daughter, 11, to use medical marijuana
An 11-year-old girl with leukemia suffers seizures due to years of chemotherapy. Her parents are suing the Chicago school district for banning her use of medical marijuana. (Source: the Mail online | Health)
Source: the Mail online | Health - January 12, 2018 Category: Consumer Health News Source Type: news

A death knell for relapsed leukemia?
(Source: ScienceNOW)
Source: ScienceNOW - January 11, 2018 Category: Science Authors: Kiberstis, P. A. Tags: twil Source Type: news

Some leukemia patients may be missing out on new treatments
(Queen Mary University of London) Patients with an aggressive form of leukemia, currently ineligible for any type of targeted therapy, may in fact benefit from some of these new drugs, according to new research by Queen Mary University of London. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2018 Category: Cancer & Oncology Source Type: news

Throwing molecular wrench into gene control machine leads to 'melting away' of leukemia
(Cold Spring Harbor Laboratory) Researchers have figured out a way to prevent MYB, one of the most potent cancer-aiding proteins, from activating genes in AML, an aggressive form of leukemia. Tested in mice, the new method resulted in dramatic cancer reduction and no harm to healthy cells. This could lead to a new therapy for AML and possibly other cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 8, 2018 Category: Biology Source Type: news

Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients
Two-years of rituximab maintenance therapy can prolong remission in selected elderly patients with chronic lymphocytic leukemia (CLL) in first remission after an abbreviated front-line course of fludarabine, cyclophosphamide and rituximab (FCR), according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Researchers detect a loophole in chronic lymphocytic leukemia treatment
(Rockefeller University Press) A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be published Jan. 4 in the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2018 Category: International Medicine & Public Health Source Type: news

Tumor suppressor gene variants identified as cancer 'double whammy' for leukemia patients
(St. Jude Children's Research Hospital) A study led by St. Jude Children's Research Hospital found germline variations in a key tumor suppressor gene that may prompt changes in treatment and follow-up care for certain high-risk leukemia patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 4, 2018 Category: Cancer & Oncology Source Type: news

Could viruses take cancer immunotherapy to the next level?
(The Ottawa Hospital) Immunotherapy, which helps the body's immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study suggests that a combination of two immunotherapies (oncolytic viruses and checkpoint inhibitors) could be much more successful. This combination could cure 60-90 percent of mice in aggressive breast cancer models. Human trials are ongoing, in other kinds of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 3, 2018 Category: Cancer & Oncology Source Type: news

Thumbs Up for Latest CAR T-Cell Approval
(MedPage Today) -- New era for lymphoma, leukemia, possibly other cancers (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 30, 2017 Category: Primary Care Source Type: news

Agios lines up another potential FDA nod with new leukemia drug
Less than five months after getting its first cancer drug approved, Cambridge-based Agios Pharmaceuticals has lined up another potential FDA nod — and the first for a medicine that it fully owns. Agios (Nasdaq: AGIO) said Tuesday that it had submitted an application for ivosidenib, a potential drug for patients with acute myeloid leukemia who have a specific genetic mutation, and whose cancer has relapsed or isn’t responding to initial treatment. The company said it had asked the FDA to review… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 26, 2017 Category: American Health Authors: Max Stendahl Source Type: news

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
(Source: Food and Drug Administration)
Source: Food and Drug Administration - December 22, 2017 Category: American Health Source Type: news

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). (Source: World Pharma News)
Source: World Pharma News - December 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Mum to have Christmas day toast with donor who saved life
Nicky Turkoz, 53, from Dorset, who had leukaemia, finally met her 'heroine' donor – healthcare assistant Annette Hamson. Rules meant that for two years they were anonymous. (Source: the Mail online | Health)
Source: the Mail online | Health - December 22, 2017 Category: Consumer Health News Source Type: news

FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response
December 22, 2017 -- The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2017 Category: Drugs & Pharmacology Source Type: news

Modern Love: Shooing Carolers Away for a Love That Stays
As Christmas nears, a young woman hospitalized with pediatric leukemia basks in a new romance even as her health fails. (Source: NYT Health)
Source: NYT Health - December 22, 2017 Category: Consumer Health News Authors: LESLIE GAUTHIER Tags: Christmas Hospitals Dating and Relationships Memorial Sloan-Kettering Cancer Center Source Type: news

Leukaemia treatment can be made more effective by using a drug for iron overload
(Imperial College London) Chemotherapy for one type of leukaemia could be improved by giving patients a drug currently used to treat an unrelated condition, new research shows. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 21, 2017 Category: Biology Source Type: news

Multifunctional protein contributes to blood cell development
(Salk Institute) Salk researchers uncover mechanism for how blood cells mature and specialize--and why errors can sometimes lead to leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2017 Category: Cancer & Oncology Source Type: news

2017 ’ s Year In Health News: Medical Breakthroughs, Opioid Crisis And More
CBS Local — There’s been plenty of progress in the medical world this year, and as a result we now know that more Americans than ever have high blood pressure, but also that coffee everyday is actually good for you. Here’s a look back at the year in health. Opioid Crisis The opioid crisis has dominated much of the health news cycle. President Trump declared the opioid crisis a national emergency earlier this year. Drug overdoses are now the leading cause of death for people under 50 in the United States. New Guidelines for High Blood Pressure The American Heart Association revised its guidelines for high ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 20, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News best of 2017 Samantha Lazarus Bennet Source Type: news

FDA Approves Pfizer ’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
December 19, 2017 -- Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Mother discovered Christmas party hangover was cancer
Elizabeth Graham, 33, of of Paisley, Scotland, felt like she'd downed 20 drinks next morning but had consumed only five. A blood test revealed that she had leukaemia, which needed urgent treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - December 19, 2017 Category: Consumer Health News Source Type: news

DNA annotations predict patient outcomes in childhood leukemia
(University of California - San Francisco) UC San Francisco physician-scientists have developed a test that can predict how patients with juvenile myelomonocytic leukemia (JMML) will respond to treatment, and may also be able to identify patients who are likely to recover spontaneously with little to no treatment. The researchers are currently optimizing the test for more routine clinical use in the United States. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 19, 2017 Category: Cancer & Oncology Source Type: news

Cancer-stricken girl blinded by protruding eyes in India
Dhanika Tripura, from Tripura in India, is suffering with acute lymphocytic leukemia. The girl was healthy before she deteriorated after suffering with itchy eyes just 6 weeks ago. (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news

What medical advancements can we expect in 2018?
In 2017, we've seen headlines about new blood pressure guidelines and the opioid crisis being declared a public health emergency. The FDA also approved gene therapy for childhood leukemia. Next year, we could see advances in gene editing to cure or prevent diseases. Dr. David Agus joins "CBS This Morning" to discuss a new shingles vaccine, the ethical questions surrounding gene editing and the importance of strong leadership when regulating medicine. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 15, 2017 Category: Consumer Health News Source Type: news

Make-A-Wish sends 7 teens to Star Wars premiere
Seven teens with life-threatening illnesses including leukemia and brain cancer had the chance to the meet the stars of The Last Jedi at the world premiere in Los Angeles. (Source: the Mail online | Health)
Source: the Mail online | Health - December 14, 2017 Category: Consumer Health News Source Type: news

ABQ CEO honored for innovative medical work
Cancer research is a fast-advancing field, using the latest technology to better understand the disease. One Albuquerque medical leader is will receive a prestigious honor for using an innovative method to discover what causes certain types of leukemia. Dr. Cheryl Willman, CEO and director of the University of New Mexico's Comprehensive Cancer Center, and Plamen B. Atanassov, director of the UNM Center for Micro-Engineered Materials and a chemical and biological engineering professor, have been… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 13, 2017 Category: American Health Authors: May Ortega Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Media News)
Source: Roche Media News - December 12, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

New discovery may enhance chemotherapy's efficiency against leukaemia
(Instituto de Medicina Molecular) Portuguese researchers have found a mechanism through which certain types of leukaemia resist chemotherapy, revealing novel molecular targets to improve this therapy's efficiency. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: news

Your NEJM Group Today: Ecthyma Gangrenosum Image / Tranexamic Acid & Epistaxis / Arizona Family Med Opportunity
Check out today's selections from NEJM Group: NEJM Clinical Practice Center: Image in Clinical Medicine: A 21-year-old woman with acute myeloid leukemia who... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 12, 2017 Category: Primary Care Source Type: news

Promising responses seen with Agios leukemia drug in study
(Reuters) - Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday. (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Blood Transfusions in Leukemia a Deterrent to Hospice Care Blood Transfusions in Leukemia a Deterrent to Hospice Care
Among patients with leukemia, transfusion dependence at end of life can be a deterrent to timely access to hospice care.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 11, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Transfusion dependence a barrier to quality end-of-life care for some with leukemia
(American Society of Hematology) For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2017 Category: Cancer & Oncology Source Type: news

Immunotherapy strategy could be beneficial for relapsed acute myeloid leukemia
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers will present preliminary results from an ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on Saturday, Dec. 9. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2017 Category: Cancer & Oncology Source Type: news

Ibrutinib and Venetoclax: Potential Combination for r/r CLL Ibrutinib and Venetoclax: Potential Combination for r/r CLL
Ibrutinib and venetoclax are already approved for the treatment of chronic lymphocytic leukemia, but new data suggest that using them together could be an option.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia
(Dana-Farber Cancer Institute) Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

For leukemia patients, transfusion needs may delay hospice care
(Brown University) Researchers report that thousands of leukemia patients who received frequent transfusions had very short stays in hospice at the end of life, suggesting that transfusion dependence presents a barrier to making meaningful use of palliative care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2017 Category: Cancer & Oncology Source Type: news

Debate on Glyphosate Use Comes to a Head in Argentina
Academics discuss the impacts on health and the environment of the use of glyphosate in Argentine agriculture, during a Dec. 6 conference at the University of Buenos Aires. Concern about this topic is now on the country’s public agenda. Credit: Daniel Gutman / IPSBy Daniel GutmanBUENOS AIRES, Dec 8 2017 (IPS)In and around the city of Rosario, where most of Argentina’s soybean processing plants are concentrated, a local law banned the use of glyphosate, the most widely-used herbicide in Argentina. But two weeks later, producers managed to exert enough pressure to obtain a promise that the ban would be overturned...
Source: IPS Inter Press Service - Health - December 8, 2017 Category: International Medicine & Public Health Authors: Daniel Gutman Tags: Active Citizens Civil Society Development & Aid Economy & Trade Editors' Choice Environment Food & Agriculture Headlines Health Latin America & the Caribbean Population Poverty & SDGs Regional Categories Source Type: news

Leukemia & Lymphoma Society awards $1.7 million in local grants
The Leukemia& Lymphoma Society is awarding more than $1.7 million grants in St. Louis to blood cancer research efforts. The local grants are part of the organization's broader research commitment of $46 million globally focused on research for blood cancer cures. Local researchers receiving funding from LLS include four Washington University medical school doctors: Dr. Takeshi Egawa, who received a career developm ent program grant; Dr Timothy Ley, who received a translational research program… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 8, 2017 Category: Health Management Authors: Angela Mueller Source Type: news

Leukemia & Lymphoma Society awards $1.7 million in local grants
The Leukemia& Lymphoma Society is awarding more than $1.7 million grants in St. Louis to blood cancer research efforts. The local grants are part of the organization's broader research commitment of $46 million globally focused on research for blood cancer cures. Local researchers receiving funding from LLS include four Washington University medical school doctors: Dr. Takeshi Egawa, who received a career developm ent program grant; Dr Timothy Ley, who received a translational research program… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 8, 2017 Category: Biotechnology Authors: Angela Mueller Source Type: news

Dr. Mohamad Cherry of Atlantic Hematology Oncology to Lead Meeting...
Mohamad Cherry, MD, will lead a major session on new discoveries about the most common type of acute adult leukemia and help present results of four major blood cancer studies at the American Society...(PRWeb December 08, 2017)Read the full story at http://www.prweb.com/releases/2017/12/prweb14994899.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 8, 2017 Category: Pharmaceuticals Source Type: news

New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Positive Overall Survival Data From Phase 3 ASPIRE Trial on KYPROLIS® (Carfilzomib) in Relapsed Multiple Myeloma to be Highlighted in Oral Presentation Results From Several Abstracts Highlight the Potential of Amgen's Bispecific T Cell Engager (BiTE®) Platform as an Innovative Approach to Treating Blood Cancers FDA Grants Priority Review for BLINCYTO (Blinatumomab) Supplemental Biologics License Application in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33...
Source: Amgen News Release - December 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Sanofi explores combination treatments for multiple myeloma in new late-stage trials
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia. (Source: World Pharma News)
Source: World Pharma News - December 7, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Majority of leukaemia patients lack access to specialist nurse
Only around a third of patients with leukaemia have access to specialist nurses, according to leading blood cancer charity. (Source: Nursing Times)
Source: Nursing Times - December 6, 2017 Category: Nursing Source Type: news

Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome MENLO PARK, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regenerative Medicine, Oncology Forty Seven, acute myeloid leukemia, Myelodysplastic Syndrome, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

Bio-Rad releases first CE-IVD digital PCR test for monitoring chronic myeloid leukemia response to therapy
(CG Life) Bio-Rad's QXDx BCR-ABL %IS Kit is the most sensitive diagnostic test available for monitoring deep molecular response of patients with chronic myeloid leukemia to tyrosine kinase inhibitor therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2017 Category: International Medicine & Public Health Source Type: news

State's stem cell agency awards nearly $8 million for new leukemia therapies
(University of California - San Diego) The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2017 Category: Cancer & Oncology Source Type: news

Missing DNA fragments hold clue to predicting childhood leukaemia relapse
(Children's Cancer Institute Australia) Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or 'microdeletions'. The risk score will allow doctors to better predict the chance of relapse of a subgroup of kids currently hidden in a lower risk group, paving the way for new treatment options. The finding was published today in the British Journal of Haematology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2017 Category: Cancer & Oncology Source Type: news

The target landscape of clinical kinase drugs
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the target spectrum of 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on the "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration of phosphoproteomic data refined drug-affected pathways, identified response markers, and strengthened rationale for combination tr...
Source: ScienceNOW - November 30, 2017 Category: Science Authors: Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., Zecha, J., Reiter, K., Qiao, H., Helm, D., Koch, H., Schoof, M., Canevari, G., Casale, E., Depaolini, S. R., Feuchtinger, A. Tags: Cell Biology, Medicine, Diseases r-articles Source Type: news